Viewing StudyNCT05033756



Ignite Creation Date: 2024-05-06 @ 4:35 PM
Last Modification Date: 2024-10-26 @ 2:13 PM
Study NCT ID: NCT05033756
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-05-07
First Post: 2021-04-03

Brief Title: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency COMPRENDO
Sponsor:
Organization: Institut fuer Frauengesundheit